A multidisciplinary study of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors

Sándor Kun, Jaida Begum, Efthimios Kyriakis, Evgenia C.V. Stamati, Thomas A. Barkas, Eszter Szennyes, Éva Bokor, Katalin E. Szabó, George A. Stravodimos, Ádám Sipos, T. Docsa, P. Gergely, Colin Moffatt, Myrto S. Patraskaki, Maria C. Kokolaki, Alkistis Gkerdi, Vassiliki T. Skamnaki, Demetres D. Leonidas, L. Somsák, Joseph M. Hayes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

3-(β-D-Glucopyranosyl)-5-substituted-1,2,4-triazoles have been revealed as an effective scaffold for the development of potent glycogen phosphorylase (GP) inhibitors but with the potency very sensitive to the nature of the alkyl/aryl 5-substituent (Kun et al., Eur. J. Med. Chem. 2014, 76, 567). For a training set of these ligands, quantum mechanics-polarized ligand docking (QM-PLD) demonstrated good potential to identify larger differences in potencies (predictive index PI = 0.82) and potent inhibitors with Ki's < 10 μM (AU-ROC = 0.86). Accordingly, in silico screening of 2335 new analogues exploiting the ZINC docking database was performed and nine predicted candidates selected for synthesis. The compounds were prepared in O-perbenzoylated forms by either ring transformation of 5-β-D-glucopyranosyl tetrazole by N-benzyl-arenecarboximidoyl chlorides, ring closure of C-(β-D-glucopyranosyl)formamidrazone with aroyl chlorides, or that of N-(β-D-glucopyranosylcarbonyl)arenethiocarboxamides by hydrazine, followed by deprotections. Kinetics experiments against rabbit muscle GPb (rmGPb) and human liver GPa (hlGPa) revealed five compounds as potent low μM inhibitors with three of these on the submicromolar range for rmGPa. X-ray crystallographic analysis sourced the potency to a combination of favorable interactions from the 1,2,4-triazole and suitable aryl substituents in the GP catalytic site. The compounds also revealed promising calculated pharmacokinetic profiles.

Original languageEnglish
Pages (from-to)266-278
Number of pages13
JournalEuropean Journal of Medicinal Chemistry
Volume147
DOIs
Publication statusPublished - Mar 10 2018

Fingerprint

Glycogen Phosphorylase
Crystallography
hydrazine
Ligands
Derivatives
Kinetics
Pharmacokinetics
Quantum theory
Mechanics
Scaffolds
Liver
Computer Simulation
Muscle
Chlorides
Catalytic Domain
Screening
X-Rays
Databases
Rabbits
X rays

Keywords

  • 1,2,4-Triazole
  • C-β-D-glucopyranosyl derivatives
  • Glycogen phosphorylase inhibitors
  • Kinetics
  • QM/MM docking
  • X-ray crystallography

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

A multidisciplinary study of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors : Computation, synthesis, crystallography and kinetics reveal new potent inhibitors. / Kun, Sándor; Begum, Jaida; Kyriakis, Efthimios; Stamati, Evgenia C.V.; Barkas, Thomas A.; Szennyes, Eszter; Bokor, Éva; Szabó, Katalin E.; Stravodimos, George A.; Sipos, Ádám; Docsa, T.; Gergely, P.; Moffatt, Colin; Patraskaki, Myrto S.; Kokolaki, Maria C.; Gkerdi, Alkistis; Skamnaki, Vassiliki T.; Leonidas, Demetres D.; Somsák, L.; Hayes, Joseph M.

In: European Journal of Medicinal Chemistry, Vol. 147, 10.03.2018, p. 266-278.

Research output: Contribution to journalArticle

Kun, S, Begum, J, Kyriakis, E, Stamati, ECV, Barkas, TA, Szennyes, E, Bokor, É, Szabó, KE, Stravodimos, GA, Sipos, Á, Docsa, T, Gergely, P, Moffatt, C, Patraskaki, MS, Kokolaki, MC, Gkerdi, A, Skamnaki, VT, Leonidas, DD, Somsák, L & Hayes, JM 2018, 'A multidisciplinary study of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors', European Journal of Medicinal Chemistry, vol. 147, pp. 266-278. https://doi.org/10.1016/j.ejmech.2018.01.095
Kun, Sándor ; Begum, Jaida ; Kyriakis, Efthimios ; Stamati, Evgenia C.V. ; Barkas, Thomas A. ; Szennyes, Eszter ; Bokor, Éva ; Szabó, Katalin E. ; Stravodimos, George A. ; Sipos, Ádám ; Docsa, T. ; Gergely, P. ; Moffatt, Colin ; Patraskaki, Myrto S. ; Kokolaki, Maria C. ; Gkerdi, Alkistis ; Skamnaki, Vassiliki T. ; Leonidas, Demetres D. ; Somsák, L. ; Hayes, Joseph M. / A multidisciplinary study of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors : Computation, synthesis, crystallography and kinetics reveal new potent inhibitors. In: European Journal of Medicinal Chemistry. 2018 ; Vol. 147. pp. 266-278.
@article{98ff269e551c443f806abf325ce67ddf,
title = "A multidisciplinary study of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors",
abstract = "3-(β-D-Glucopyranosyl)-5-substituted-1,2,4-triazoles have been revealed as an effective scaffold for the development of potent glycogen phosphorylase (GP) inhibitors but with the potency very sensitive to the nature of the alkyl/aryl 5-substituent (Kun et al., Eur. J. Med. Chem. 2014, 76, 567). For a training set of these ligands, quantum mechanics-polarized ligand docking (QM-PLD) demonstrated good potential to identify larger differences in potencies (predictive index PI = 0.82) and potent inhibitors with Ki's < 10 μM (AU-ROC = 0.86). Accordingly, in silico screening of 2335 new analogues exploiting the ZINC docking database was performed and nine predicted candidates selected for synthesis. The compounds were prepared in O-perbenzoylated forms by either ring transformation of 5-β-D-glucopyranosyl tetrazole by N-benzyl-arenecarboximidoyl chlorides, ring closure of C-(β-D-glucopyranosyl)formamidrazone with aroyl chlorides, or that of N-(β-D-glucopyranosylcarbonyl)arenethiocarboxamides by hydrazine, followed by deprotections. Kinetics experiments against rabbit muscle GPb (rmGPb) and human liver GPa (hlGPa) revealed five compounds as potent low μM inhibitors with three of these on the submicromolar range for rmGPa. X-ray crystallographic analysis sourced the potency to a combination of favorable interactions from the 1,2,4-triazole and suitable aryl substituents in the GP catalytic site. The compounds also revealed promising calculated pharmacokinetic profiles.",
keywords = "1,2,4-Triazole, C-β-D-glucopyranosyl derivatives, Glycogen phosphorylase inhibitors, Kinetics, QM/MM docking, X-ray crystallography",
author = "S{\'a}ndor Kun and Jaida Begum and Efthimios Kyriakis and Stamati, {Evgenia C.V.} and Barkas, {Thomas A.} and Eszter Szennyes and {\'E}va Bokor and Szab{\'o}, {Katalin E.} and Stravodimos, {George A.} and {\'A}d{\'a}m Sipos and T. Docsa and P. Gergely and Colin Moffatt and Patraskaki, {Myrto S.} and Kokolaki, {Maria C.} and Alkistis Gkerdi and Skamnaki, {Vassiliki T.} and Leonidas, {Demetres D.} and L. Soms{\'a}k and Hayes, {Joseph M.}",
year = "2018",
month = "3",
day = "10",
doi = "10.1016/j.ejmech.2018.01.095",
language = "English",
volume = "147",
pages = "266--278",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - A multidisciplinary study of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors

T2 - Computation, synthesis, crystallography and kinetics reveal new potent inhibitors

AU - Kun, Sándor

AU - Begum, Jaida

AU - Kyriakis, Efthimios

AU - Stamati, Evgenia C.V.

AU - Barkas, Thomas A.

AU - Szennyes, Eszter

AU - Bokor, Éva

AU - Szabó, Katalin E.

AU - Stravodimos, George A.

AU - Sipos, Ádám

AU - Docsa, T.

AU - Gergely, P.

AU - Moffatt, Colin

AU - Patraskaki, Myrto S.

AU - Kokolaki, Maria C.

AU - Gkerdi, Alkistis

AU - Skamnaki, Vassiliki T.

AU - Leonidas, Demetres D.

AU - Somsák, L.

AU - Hayes, Joseph M.

PY - 2018/3/10

Y1 - 2018/3/10

N2 - 3-(β-D-Glucopyranosyl)-5-substituted-1,2,4-triazoles have been revealed as an effective scaffold for the development of potent glycogen phosphorylase (GP) inhibitors but with the potency very sensitive to the nature of the alkyl/aryl 5-substituent (Kun et al., Eur. J. Med. Chem. 2014, 76, 567). For a training set of these ligands, quantum mechanics-polarized ligand docking (QM-PLD) demonstrated good potential to identify larger differences in potencies (predictive index PI = 0.82) and potent inhibitors with Ki's < 10 μM (AU-ROC = 0.86). Accordingly, in silico screening of 2335 new analogues exploiting the ZINC docking database was performed and nine predicted candidates selected for synthesis. The compounds were prepared in O-perbenzoylated forms by either ring transformation of 5-β-D-glucopyranosyl tetrazole by N-benzyl-arenecarboximidoyl chlorides, ring closure of C-(β-D-glucopyranosyl)formamidrazone with aroyl chlorides, or that of N-(β-D-glucopyranosylcarbonyl)arenethiocarboxamides by hydrazine, followed by deprotections. Kinetics experiments against rabbit muscle GPb (rmGPb) and human liver GPa (hlGPa) revealed five compounds as potent low μM inhibitors with three of these on the submicromolar range for rmGPa. X-ray crystallographic analysis sourced the potency to a combination of favorable interactions from the 1,2,4-triazole and suitable aryl substituents in the GP catalytic site. The compounds also revealed promising calculated pharmacokinetic profiles.

AB - 3-(β-D-Glucopyranosyl)-5-substituted-1,2,4-triazoles have been revealed as an effective scaffold for the development of potent glycogen phosphorylase (GP) inhibitors but with the potency very sensitive to the nature of the alkyl/aryl 5-substituent (Kun et al., Eur. J. Med. Chem. 2014, 76, 567). For a training set of these ligands, quantum mechanics-polarized ligand docking (QM-PLD) demonstrated good potential to identify larger differences in potencies (predictive index PI = 0.82) and potent inhibitors with Ki's < 10 μM (AU-ROC = 0.86). Accordingly, in silico screening of 2335 new analogues exploiting the ZINC docking database was performed and nine predicted candidates selected for synthesis. The compounds were prepared in O-perbenzoylated forms by either ring transformation of 5-β-D-glucopyranosyl tetrazole by N-benzyl-arenecarboximidoyl chlorides, ring closure of C-(β-D-glucopyranosyl)formamidrazone with aroyl chlorides, or that of N-(β-D-glucopyranosylcarbonyl)arenethiocarboxamides by hydrazine, followed by deprotections. Kinetics experiments against rabbit muscle GPb (rmGPb) and human liver GPa (hlGPa) revealed five compounds as potent low μM inhibitors with three of these on the submicromolar range for rmGPa. X-ray crystallographic analysis sourced the potency to a combination of favorable interactions from the 1,2,4-triazole and suitable aryl substituents in the GP catalytic site. The compounds also revealed promising calculated pharmacokinetic profiles.

KW - 1,2,4-Triazole

KW - C-β-D-glucopyranosyl derivatives

KW - Glycogen phosphorylase inhibitors

KW - Kinetics

KW - QM/MM docking

KW - X-ray crystallography

UR - http://www.scopus.com/inward/record.url?scp=85042026889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042026889&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.01.095

DO - 10.1016/j.ejmech.2018.01.095

M3 - Article

C2 - 29453094

AN - SCOPUS:85042026889

VL - 147

SP - 266

EP - 278

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -